JERSEY CITY, N.J., April 3, 2025 /PRNewswire/ -- Mitsubishi Tanabe Pharma America, Inc. (MTPA) announced 11 presentations will be shared at the American Academy of Neurology (AAN) 2025 Annual ...

"These findings help build upon our understanding of edaravone's potential effects in ALS," said Gustavo A. Suarez Zambrano, M.D., Vice President of Medical Affairs at MTPA. "By modulating TDP-43 ...

Arbitrability of healthcare and medical tourism Conflicts in India A comparative study of US & EU Jurisdictions. Abstract: Paper focuses on arbitrability of medical disputes and m ...

Takeda Pharmaceutical Company Limited; Xenon Pharmaceuticals Inc.; Voyager Therapeutics, Inc.; Mitsubishi Tanabe Pharma ...

Earlier that month, Bain Capital acquired Japanese drugmaker Mitsubishi Tanabe Pharma for 510 billion Japanese yen ($3.3 billion), setting up an independent pharma from parent company Mitsubishi ...

In a phase 3, open-label safety extension study, researchers evaluated the safety of oral edaravone in patients with amyotrophic lateral sclerosis over 96 weeks.

Bain Capital is in talks to acquire Mitsubishi Chemical Group’s pharmaceutical business in a potential multibillion-dollar deal, a person familiar with the matter said, a transaction that could ...

Adding narrowband ultraviolet B (UVB) phototherapy to oral treatment with ritlecitinib (Litfulo) enhanced repigmentation in ...

It also agreed to buy medical firm Mitsubishi Tanabe Pharma. Private equity fundraising in Asia has slowed down as the global economic outlook dims. The total amount raised last year in Asia fell to ...